中商官网
研究报告
翰森制药（HK3692）
| 科目\年度 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
原始货币 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 审计意见 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 报表核心指标 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 现金及现金等价物净增加额 |
113779.80 | -359538.20 | 343674.50 | -401201.20 | 373468.10 | -151927.60 | 424681.80 | 68348.30 | 5750.60 | 2748.70 | -5619.80 |
| 经营活动现金流量净额 |
673824.60 | 386235.50 | 311646.80 | 274120.50 | 257706.20 | 239047.90 | 332968.90 | 207222.70 | 140225.20 | 124650.70 | 114547.10 |
| 投资活动现金流量净额 |
-715456.80 | -139179.20 | 107397.20 | -593507.30 | -225915.70 | -287412.70 | -707559.90 | -138874.40 | -61427.10 | 82953.80 | -59470.70 |
| 融资活动现金流量净额 |
155412.00 | -606594.50 | -75369.49 | -81814.40 | 341677.60 | -103562.80 | 799272.80 | -- | -73047.50 | -204855.80 | -60696.20 |
| 现金及现金等价物期末余额 |
340891.90 | 232270.10 | 598051.30 | 266613.20 | 671870.90 | 306331.60 | 534485.90 | 96483.09 | 26644.40 | 20869.90 | 16119.20 |
| 经营活动现金流量净额 |
673824.60 | 386235.50 | 311646.80 | 274120.50 | 257706.20 | 239047.90 | 332968.90 | 207222.70 | 140225.20 | 124650.70 | 114547.10 |
| 折旧与摊销 |
39301.80 | 40134.90 | 36638.10 | 34413.00 | 27799.50 | 23327.40 | 20155.40 | 15909.60 | 13801.30 | 12130.20 | 11263.90 |
| 营运资金变动 |
154756.80 | 3616.30 | 25723.20 | -30578.20 | -42837.70 | -21614.80 | 83245.20 | -4385.80 | -41295.40 | -35848.00 | -29673.70 |
| 投资活动现金流量净额 |
-715456.80 | -139179.20 | 107397.20 | -593507.30 | -225915.70 | -287412.70 | -707559.90 | -138874.40 | -61427.10 | 82953.80 | -59470.70 |
| 资本性支出 |
48946.10 | 52493.50 | 36252.40 | 29182.30 | 47544.10 | 143925.00 | 59729.00 | 40721.60 | 26308.70 | 27348.90 | 24317.60 |
| 投资购买 |
-3307655.00 | -10857.10 | -64065.60 | -32373.40 | -252441.50 | -574048.40 | -304087.20 | -- | -474474.20 | -477313.40 | -1220550.00 |
| 融资活动现金流量净额 |
155412.00 | -606594.50 | -75369.49 | -81814.40 | 341677.60 | -103562.80 | 799272.80 | -- | -73047.50 | -204855.80 | -60696.20 |
| 股份回购 |
-- | -3369.30 | -11486.50 | -7661.80 | -5796.90 | -- | -- | -- | -- | -- | -- |
| 支付股息 |
-201218.40 | -185834.80 | -65208.20 | -71218.40 | -38086.60 | -420000.00 | -150000.00 | -- | -40413.40 | -236850.70 | -64423.20 |
| 股票发行 |
358868.30 | 3318.60 | 3798.70 | 1314.30 | 1511.10 | 317197.30 | 953439.60 | -- | -- | 130244.90 | -- |
| 现金及现金等价物净增加额 |
113779.80 | -359538.20 | 343674.50 | -401201.20 | 373468.10 | -151927.60 | 424681.80 | 68348.30 | 5750.60 | 2748.70 | -5619.80 |
| 加：现金及现金等价物期初余额 |
232270.10 | 598051.30 | 266613.20 | 671870.90 | 306331.60 | 534485.90 | 96483.09 | 26644.40 | 20869.90 | 16119.20 | 21739.00 |
| 汇率变动对现金及现金等价物的影响 |
-5158.00 | -6243.00 | -12236.40 | -4056.50 | -7928.80 | -76226.70 | 13321.00 | 1490.40 | 23.90 | 2002.00 | -- |
| 现金及现金等价物期末余额 |
340891.90 | 232270.10 | 598051.30 | 266613.20 | 671870.90 | 306331.60 | 534485.90 | 96483.09 | 26644.40 | 20869.90 | 16119.20 |